PT  - JOURNAL ARTICLE
AU  - MONIKA KMETOVA SIVONOVA
AU  - JANA JURECEKOVA
AU  - PETER KAPLAN
AU  - MARK HIVES
AU  - MARIAN GRENDAR
AU  - ANNA TOMASCOVA
AU  - ROBERT DUSENKA
AU  - HENRIETA DROBKOVA
AU  - DANIEL EVIN
AU  - JAN KLIMENT
TI  - Association of <em>MDM2 T309G</em> (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population
AID  - 10.21873/anticanres.14646
DP  - 2020 Nov 01
TA  - Anticancer Research
PG  - 6257--6264
VI  - 40
IP  - 11
4099  - http://ar.iiarjournals.org/content/40/11/6257.short
4100  - http://ar.iiarjournals.org/content/40/11/6257.full
SO  - Anticancer Res2020 Nov 01; 40
AB  - Background/Aim: The aim of this study was to evaluate the relationship between MDM2 T309G polymorphism and prostate cancer risk in the Slovak population and the association of this polymorphism with MDM2 expression and clinicopathological features. Materials and Methods: The MDM2 T309G polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 506 prostate cancer patients and 592 controls. Quantitative real-time (RT)-PCR and western blot analysis were applied to examine MDM2 expression in 47 prostate cancer tissues and 43 benign prostatic hyperplasia (BPH) tissues. Results: A decreased risk of prostate cancer in men carrying the GG genotype in comparison with the TT genotype was found. A decrease in the relative MDM2 mRNA and protein levels was found in prostate cancer tissues among patients with the MDM2 GG genotype. Conclusion: There is a potentially protective effect of the MDM2 GG genotype on the risk of prostate cancer in the Slovak male population.